Overview
Tetanus, also known as lockjaw, is an acute and potentially life-threatening infectious disease caused by the neurotoxin tetanospasmin produced by the anaerobic bacterium Clostridium tetani. It is not a genetic disorder but rather an acquired condition that occurs when bacterial spores enter the body through wounds, cuts, or other breaks in the skin. The toxin affects the nervous system by blocking inhibitory neurotransmitters in the central nervous system, leading to unopposed muscle contraction and spasm. Tetanus primarily affects the neuromuscular system and can involve the entire body. The disease is characterized by painful muscle stiffness and spasms, typically beginning with the jaw muscles (trismus or lockjaw) and neck, then progressing to involve the trunk and extremities. Generalized tetanus, the most common form, can cause opisthotonus (severe arching of the back), difficulty swallowing, breathing difficulties, autonomic dysfunction (fluctuations in blood pressure and heart rate), and potentially fatal respiratory failure. Neonatal tetanus (ICD-10: A33) occurs in newborns, usually through infection of the umbilical stump, and is a major cause of neonatal mortality in developing countries. Obstetrical tetanus (ICD-10: A34) occurs during or after pregnancy. Tetanus is entirely preventable through vaccination with tetanus toxoid-containing vaccines. Treatment includes wound care, administration of human tetanus immunoglobulin (TIG) to neutralize unbound toxin, antibiotics (typically metronidazole), muscle relaxants such as benzodiazepines, and supportive care in an intensive care setting. Mechanical ventilation may be required in severe cases. Despite advances in critical care, the case fatality rate remains significant, particularly in neonatal tetanus and in regions with limited access to healthcare. The disease does not confer natural immunity, so vaccination after recovery is essential.
Clinical phenotype terms— hover any for plain English:
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
7 eventsUniversity of Birmingham — NA
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Lanzhou Institute of Biological Products Co., Ltd — PHASE1
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Sinovac Life Sciences Co., Ltd. — PHASE1, PHASE2
Genrix (Shanghai) Biopharmaceutical Co., Ltd. — PHASE3
Changchun BCHT Biotechnology Co. — EARLY_PHASE1
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Tetanus.
3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Tetanus.
Community
No community posts yet. Be the first to share your experience with Tetanus.
Start the conversation →Latest news about Tetanus
Disease timeline:
New recruiting trial: A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
A new clinical trial is recruiting patients for Tetanus
New recruiting trial: A Registry: Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
A new clinical trial is recruiting patients for Tetanus
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Tetanus
What is Tetanus?
Tetanus, also known as lockjaw, is an acute and potentially life-threatening infectious disease caused by the neurotoxin tetanospasmin produced by the anaerobic bacterium Clostridium tetani. It is not a genetic disorder but rather an acquired condition that occurs when bacterial spores enter the body through wounds, cuts, or other breaks in the skin. The toxin affects the nervous system by blocking inhibitory neurotransmitters in the central nervous system, leading to unopposed muscle contraction and spasm. Tetanus primarily affects the neuromuscular system and can involve the entire body. Th
Are there clinical trials for Tetanus?
Yes — 3 recruiting clinical trials are currently listed for Tetanus on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Tetanus?
16 specialists and care centers treating Tetanus are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.